Month: September 2022

CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine The Omicron BA.1-adapted bivalent COVID-19 vaccine combines 15 µg of mRNA encoding the SARS-CoV-2 wild-type spike protein which also in the Original Pfizer-BioNTech COVID-19 Vaccine with 15 µg of mRNA encoding the spike protein of the Omicron BA.1 variant Omicron BA.1-adapted bivalent vaccine is available to ship immediately to support the start of European vaccination campaigns within the coming days  NEW YORK and MAINZ, GERMANY, September 1, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a 30 µg booster dose of their Omicron BA.1- Bivalent COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.1 15/15 µg) has been recommended for conditional marketing authorization...

BRENTWOOD, Tenn., Sept. 01, 2022 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”), announces today it is accepting patients for medical weight loss services at IMAC Regeneration Centers. The medical weight loss service will launch in three facilities this month. “We are excited about the launch of medical weight loss in IMAC Regeneration Centers. There was significant effort applied to develop and launch this service and we believe it can have a significant impact on our patients’ rehabilitative process while also introducing new patients to the IMAC orthopedic service line,” said Jeffrey Ervin, IMAC’s Chief Executive Officer. “Obesity is the second leading cause of back pain. Therefore, implementing the weight loss service gives us another tool to assist consumers in their battle against chronic...

Downing Strategic Micro-Cap Investment Trust Plc  LEI Code: 213800QMYPUW4POFFX69  Net Asset Values  The Company announces the following, all of which is unaudited:  Total Assets – including current period revenue* at 31 August 2022 £39.46mNet Assets – including current period revenue* at 31 August 2022 £39.46mNumber of shares in issue (excluding treasury): 49,519,882   The Net Asset Value (NAV) per share at 31 August 2022 was:  Per Ordinary share (bid price) – including current period revenue* 79.68pPer Ordinary share (bid price) – excluding current period revenue* 79.21p   Ordinary share price  60.80pPremium/(Discount) to NAV (including current period revenue) (23.70%)   * Current period revenue covers the period 01/03/2022 to 31/08/2022 and includes undistributed...

SANTA MONICA, CA, Sept. 01, 2022 (GLOBE NEWSWIRE) — Olive Tree People Inc., a subsidiary of Oliveda International, Inc. (OTC Pink: OLVI), is pleased to announce that beginning today, the company will be spreading awareness of a new generation of Waterless Holistic Skincare with up to 58 Executive Sales Representatives and exclusively to 3,875 spas in the United States. Olive Tree People’s mission is to heal the world with the power of our mountain olive trees.   We start with Oliveda and the Olive Tree Therapy, 10 years in 14 days, and LA Dope Holistic CBD Beauty Therapy exclusively in 3,875 spas and even more estheticians as ambassadors for waterless beauty in the U.S. and then go from there into the world. It is above all the estheticians in the spas who, with their love and dedication to their profession, live a vocation that...

WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Jonathan “Breck” Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company’s prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell® device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Mr. Harmel brings 15 years of experience in high growth medical technology and device sales, including building and managing successful sales teams on a national scale. Mr. Harmel was most recently...

SCOTTSDALE, Ariz., Sept. 01, 2022 (GLOBE NEWSWIRE) — AMMO, Inc. (Nasdaq: POWW, POWWP) (“AMMO” or the “Company”) the owner of GunBroker.com, the largest online marketplace serving the firearms and shooting sports industries, and a leading vertically integrated producer of high-performance ammunition and components, will host a ribbon cutting ceremony at its new state-of-the-art production facility located at 6311 West Custer Street in Manitowoc, Wisconsin at 12:00 p.m. CDT on September 22nd. The ceremony is open to the public. Manitowoc Mayor Justin Nickels and other state and local officials will be on site at the event along with AMMO’s Chairman & CEO, Fred Wagenhals, his senior management team, AMMO Board members, including Rusty Wallace and Richard Childress, who are also members of the NASCAR Hall of Fame. The new facility...

Nicole Lemerond, CFA, Brings Healthcare Finance Expertise to the GeoVax Board ATLANTA, GA, Sept. 01, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it has appointed Nicole Lemerond, CFA, to its Board of Directors. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking, mergers/acquisitions, and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Her breadth of industry expertise includes providers, payors, medical device manufacturers, HCIT providers, pharmaceutical and life sciences companies. Throughout...

Deeper collaboration capabilities, expanded financial metrics and enhanced security improve efficiencies and decrease time to value for companies using Sopheon Accolade® MINNEAPOLIS, Sept. 01, 2022 (GLOBE NEWSWIRE) — Sopheon, the leading international provider of software and services for Innovation Management solutions, today announced a series of enhancements and additions to its award-winning innovation management product, Accolade®. Sopheon customers will benefit from stronger collaboration capabilities, expanded data metrics and additional financial modeling, all within a highly secure environment. Using Accolade, Sopheon’s long-standing blue-chip customers across a diverse range of industries have experienced superior strategy-to-execution performance, reduced time-to-market, improved efficiency, and greater product success...